--- title: 'Quality Assurance Director / Sr. Director (GVP/PV) at BridgeBio Pharma' canonical: 'https://feeny.ai/job/quality-assurance-director-sr-director-gvp-pv-bridgebio-pharma-san-francisco-1gfcqbgcy6px' type: 'job' last_seen: '2026-09-16' --- # Quality Assurance Director / Sr. Director (GVP/PV) at BridgeBio Pharma - **Company:** BridgeBio Pharma - **Location:** San Francisco, CA - **Compensation:** $214k–$280k - **Posted:** 2026-03-11 - **Last confirmed live:** 2026-09-16 - **Apply:** https://job-boards.greenhouse.io/bridgebio/jobs/5072937007 ## Job description Mavericks Wanted When was the last time you achieved the impossible? If that thought feels overwhelming, you might want to pause here, but if it sparks excitement...read on In 2015, we pioneered a “moneyball for biotech” approach, pooling projects and promising early-stage research from academia together under one financial umbrella to reduce risk and unleash innovation. This model allows science and small teams of experts to lead the way. We build bridges to groundbreaking advancements in rare disease, and develop life-changing medicines for patients with unmet needs as fast as humanly possible. Together we define white space, push boundaries, and empower people to solve problems. If you're someone who defies convention, join us and work alongside some of the most respected minds in the industry. Together, we'll ask "why not?" and help reengineer the future of biopharma. At BridgeBio, we value curiosity and experimentation—including the ethical & thoughtful use of AI to improve clarity, speed, and quality of work. Company Overview BridgeBio is a biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. We bridge the gap between remarkable advancements in genetic science in academic institutions and the delivery of meaningful medicines to patients. Founded in 2015, the company has built a portfolio of 20+ drug development programs ranging from preclinical to late-stage development in multiple therapeutic areas including genetic dermatology, precision oncology, cardiology, endocrinology, neurology, pulmonology, and renal disease, with two approved drugs. Our focus on scientific excellence and rapid execution aims to translate today’s discoveries into tomorrow’s medicines. We have U.S. offices in San Francisco, Palo Alto, and Raleigh, with small satellites in other parts of the country. We also have international offices in Montreal, Canada, and Zurich, Switzerland, and are expanding across Europe. To learn more about our story and company culture, visit us at [bridgebio.com](https://bridgebio.com/). ## What You’ll Do The Director / Senior Director, Quality Assurance is responsible for managing and overseeing the Good Pharmacovigilance Practices (GVP) quality and compliance program at Eidos Therapeutics and other assigned BridgeBio affiliate companies. It requires strong judgement skills and business acumen in order to advise internal and external key stakeholders on interpretation and compliance with FDA, EMA, MHRA and international pharmacovigilance (PV) regulations/guidelines; corporate policies; and standard operating procedures (SOPs). This individual will be a lead point of contact in the preparation and management of GVP regulatory inspection activities. ## Responsibilities - Provide strategic and operational guidance to the organization, including, drug safety/pharmacovigilance, medical affairs, regulatory, commercial, clinical operations and outsourcing functions, to align with company procedures, regulatory requirements and best practice - Support the internal and external GVP audit program - Oversee audit schedule and the execution of the audit program - Lead or co-lead auditor on PV audits as needed - Review and/or approval of audit reports and corrective and preventive action (CAPA) responses - Maintain and contribute of audit and quality data for the Pharmacovigilance System Master File (PSMF) - Core GVP regulatory inspection team member - Lead or participate in inspection readiness activities - Host or support of regulatory inspections - Perform quality review of inspection requests - Oversee the development and tracking of regulatory responses/commitments - Review of Quality Agreements and PV/Safety Data Exchange Agreements (PVA/SDEA) to assess quality standards and regulatory compliance requirements - Participate in the investigation and assessment of PV/GxP-related quality events and provide input on proposed CAPAs - Develop, generate and present PV quality/compliance metrics for trending and process improvement - Provide quality oversight on PV-related computer system validation projects and maintenance of systems - Collaborate with Eidos and BridgeBio affiliate companies to develop and continuously improve processes and systems, including policies, SOPs and training plans - Partner cross-functionally to support the business with compliance or quality issues/concerns by ensuring appropriate evaluation, mitigation and escalation to Executive Management - Keep abreast of changes in regulations and enforcement actions and make recommendations for changes to policies and practices as needed Where You’ll Work This is a hybrid role and will require in-office collaboration in our San Francisco Office. ## Who You Are - Bachelor’s degree with 10-15+ years of GVP quality and compliance experience within a biopharmaceutical company, or contract research organization - Current knowledge of global GVP regulations and guidelines – US Code of Federal Regulations, EMA, MHRA, and ICH Guidelines - Ability to engage in cross-functional interactions with internal and external staff - Has a comprehensive understanding of current approaches in industry and the ability to incorporate them into Eidos and BridgeBio affiliate programs - Applies strong analytical and business communication skills At BridgeBio, we strive to provide a market-competitive total rewards package, including base pay, an annual performance bonus, company equity, and generous health benefits. Below is the anticipated salary range for candidates for this role who will work in California. The final salary offered to a successful candidate will depend on several factors that may include but are not limited to the type and length of experience within the job, type, and length of experience within the industry, educational background, location of residence and performance during the interview process. BridgeBio is a multi-state employer, and this salary range may not reflect positions based in other states. Salary $213,700—$280,000 USD As a global company, our comprehensive benefits may vary based on location.  We have high expectations for our team members. We make sure those working hard for patients are rewarded and cared for in return. For BridgeBio Full-Time U.S Based Roles: Financial & Rewards - Market-leading compensation - 401(k) with employer match - Employee Stock Purchase Program (ESPP) - Pre-tax commuter benefits (transit and parking) - Referral bonus for hired candidates - Subsidized lunch and parking on in-office days Health & Well-Being - 100% employer-paid medical, dental, and vision premiums for you and your dependents - Health Savings Account (HSA) with annual employer contributions, plus Flexible Spending Accounts (FSA) - Fertility & family-forming benefits - Expanded mental health support (therapy and coaching resources) - Hybrid work model with flexibility - Flexible, “take-what-you-need” paid time off and company-paid holidays - Comprehensive paid medical and parental leave to care for yourself and your family Skill Development & Career Paths: - People are part of our growth and success story - from discovery to active drug trials and FDA pipelines, there are endless opportunities for skill development and internal mobility - We provide career pathing through regular feedback, continuous education and professional development programs via LinkedIn Learning, LifeLabs, & BetterUp Coaching - We celebrate strong performance with financial rewards, peer-to-peer recognition, and growth opportunities ## About BridgeBio Pharma ## Company Overview - **One-liner**: BridgeBio Pharma develops transformative medicines for genetic conditions, using a decentralized hub-and-spoke model to accelerate drug development from early research to commercialization. - **Entity Type**: Public (Nasdaq: BBIO) - **Headquarters**: Palo Alto, California, USA (with hybrid offices in San Francisco, CA) - **Founded**: Not explicitly stated in provided sources; the company references “over the past 10 years” as of 2026, suggesting founding around 2015–2016. - **Founders**: Not publicly available from provided sources. ## Core Business - **Primary industry**: Biotechnology / Genetic disease therapeutics - **Target customers**: Patients living with genetic conditions, healthcare providers, payers, and academic research partners - **Mission**: “To develop transformative medicines for genetic conditions” and “bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations.” ## Products & Services BridgeBio’s pipeline includes both approved therapies and investigational candidates across dozens of indications. Key offerings: - **Acoramidis**: Approved for transthyretin amyloidosis (ATTR) – a first-in-class treatment with $8B+ peak year sales potential. - **Infigratinib**: Phase 3 completed for achondroplasia; published in the *New England Journal of Medicine* (2026). - **BBP-418**: Investigational for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9). - **Encaleret**: Investigational for Autosomal Dominant Hypocalcemia Type 1 (ADH1). - **BBP-812**: Investigational for Canavan Disease. - **BridgeBio Oncology Therapeutics (BBOT)**: Subsidiary focused on RAS and PI3Kα-driven cancers. - **GondolaBio**: Subsidiary developing bioavailable small molecule inhibitors for oncology. - **Other programs**: Covering hypochondroplasia, chronic hypoparathyroidism, and more. The company has received **3 FDA approvals** and has over **70+ peer-reviewed publications**. ## Market Standing - **Valuation / Market Cap**: Not explicitly stated in provided data; as a public company, current market cap can be found on financial platforms (e.g., ~$8B based on peak sales potential, but not a direct valuation number). - **Key Metric**: **3 FDA-approved medicines**; **2000+ patients enrolled** in global clinical trials; **6 Phase 3 trials** conducted over the past 10 years. - **Notable Investors / Partners**: Not detailed in provided sources, but the company partners with leading academic institutions to advance early-stage research. - **Growth Signals**: Recent publication of Phase 3 PROPEL 3 trial results in NEJM (June 2026); expansion into oncology via BBOT and GondolaBio; 100% of pipeline is first-in-class or best-in-class; 48 unique disease indications targeted. ## Competitive Advantages - **Hub-and-spoke model**: Decentralized structure where autonomous affiliate teams (spokes) focus on specific conditions, while a central hub provides clinical, regulatory, and commercial expertise. This enables speed, scalability, and risk reduction. - **First-in-class / best-in-class focus**: 100% of pipeline aims to be first or best in class, targeting underserved genetic conditions with clear biological rationale. - **Speed and adaptability**: The model allows rapid pivoting to the most promising opportunities, reducing development timelines compared to traditional biotech. - **Strong scientific foundation**: Over 70 peer-reviewed papers and collaborations with top academic institutions. ## Strategic Focus - **Advance late-stage pipeline**: Prioritize Phase 3 programs (e.g., infigratinib for achondroplasia, acoramidis for ATTR) and seek additional FDA approvals. - **Expand into oncology**: Leverage subsidiaries BBOT and GondolaBio to address RAS/PI3Kα-driven cancers. - **Maintain urgency**: “Every minute counts” – continue to operate with speed and autonomy to bring treatments to patients faster. - **Build on commercial success**: Leverage existing approved products to fund further R&D and expand global reach. ## Why Work Here - **Award-winning culture**: Named **#1 Best Place to Work** by BioSpace (2026, small biotech category) with an **88% employee engagement score** in 2025. - **Flexible work model**: Hybrid policy with offices in San Francisco and Palo Alto, CA; “flexible working model” emphasized. - **Compensation and benefits**: Market-leading pay, comprehensive healthcare, and strong emphasis on growth and internal mobility. - **Impact-driven mission**: Work on transformative treatments for genetic conditions where patient need is urgent – “Impatient for Patients” is a core mantra. - **Values**: Put patients first, let science speak, think independently, speak up, and act with urgency. The culture is described as “high on standards, low on convention.” - **Growth opportunities**: 113 open jobs (as of mid-2026) across functions including clinical, regulatory, manufacturing, commercial, and corporate; talent community available for future roles. ## Sources 1. [bridgebio.com](https://bridgebio.com/) – Home page with pipeline overview and $8B peak sales potential 2. [bridgebio.com/about](https://bridgebio.com/about) – Company description, hub-and-spoke model, and key metrics 3. [bridgebio.com/careers](https://bridgebio.com/careers) – Careers page with awards, culture, and benefits 4. [investor.bridgebio.com](https://investor.bridgebio.com/overview/default.aspx) – Investor relations overview, latest news, and corporate presentation 5. [job-boards.greenhouse.io/bridgebio](http://job-boards.greenhouse.io/bridgebio) – Current job listings (113 roles) and departmental categories ## Other roles at BridgeBio Pharma - [Director, Regulatory CMC](https://feeny.ai/job/director-regulatory-cmc-bridgebio-pharma-united-states-ebrxcpgtzc77) — United States - [Sr. Director/ Exec. Director- CMC, Drug Product](https://feeny.ai/job/sr-director-exec-director-cmc-drug-product-bridgebio-pharma-san-francisco-q4qjnhbq8gr4) — San Francisco, CA - [Family Access Manager (FAM), Skeletal Dysplasia - SOUTH EAST](https://feeny.ai/job/family-access-manager-fam-skeletal-dysplasia-south-east-bridgebio-pharma-united-s8j14mgc07nz) — United States - [Family Access Manager (FAM), Skeletal Dysplasia - EAST](https://feeny.ai/job/family-access-manager-fam-skeletal-dysplasia-east-bridgebio-pharma-united-states-jy27te2gkqcf) — United States - [Family Access Manager (FAM), Skeletal Dysplasia - MID-ATLANTIC](https://feeny.ai/job/family-access-manager-fam-skeletal-dysplasia-mid-atlantic-bridgebio-pharma-prrt1cr049ev) — United States - [Family Access Manager (FAM), Skeletal Dysplasia - MIDWEST](https://feeny.ai/job/family-access-manager-fam-skeletal-dysplasia-midwest-bridgebio-pharma-united-7cm4g2xyrx8d) — United States - [Family Access Manager (FAM), Skeletal Dysplasia - South West](https://feeny.ai/job/family-access-manager-fam-skeletal-dysplasia-south-west-bridgebio-pharma-united-cnw8gmc9bmtp) — United States - [Family Access Manager (FAM), Skeletal Dyplasia - WEST](https://feeny.ai/job/family-access-manager-fam-skeletal-dyplasia-west-bridgebio-pharma-united-states-v27ht06awxjg) — United States - [Senior Manager, Computer System Validation QA](https://feeny.ai/job/senior-manager-computer-system-validation-qa-bridgebio-pharma-united-states-8gk11e5n2xrb) — United States - [Associate Director, HCP Marketing](https://feeny.ai/job/associate-director-hcp-marketing-bridgebio-pharma-san-francisco-141ggr9213nb) — San Francisco, CA